Dr. Yoon is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
200 1st Street SW
Rochester, MN 55905
Summary
- I am a board-certified medical oncologist with a clinical specialization in GI cancers and cancers of unknown primary (CUP) My research focuses on clinical trials of novel agents and translational investigations in gastroesophageal and colorectal cancer and in CUP.
Education & Training
Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2004 - 2008
Yale-New Haven Medical CenterResidency, Internal Medicine, 2001 - 2004
Yale School of MedicineClass of 2001
Johns Hopkins University Schools of Medicine and Public HealthMHS, Clinical Investigation
Certifications & Licensure
MN State Medical License 2008 - 2025
MD State Medical License 2004 - 2009- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Genes in Predicting Outcome in Patients With Esophageal Cancer Treated With Cisplatin, Radiation Therapy, and Surgery Start of enrollment: 2007 May 11
- A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies Start of enrollment: 2011 Apr 01
- Pembrolizumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Adult Patients With Locally Advanced Gastroesophageal Junction or Gastric Cardia Cancer That Can Be Removed by Surgery Start of enrollment: 2016 Jun 24
- Join now to see all
Publications & Presentations
PubMed
- 678 citationsGastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.Jaffer A Ajani, Thomas A D'Amico, David J Bentrem, Joseph Chao, David Cooke
Journal of the National Comprehensive Cancer Network. 2022-02-01 - 1235 citationsSafety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-05...Charles S. Fuchs, Toshihiko Doi, Raymond Jang, Kei Muro, Taroh Satoh
JAMA Oncology. 2018-05-10 - 189 citationsEsophageal and Esophagogastric Junction Cancers, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology.Jaffer A Ajani, Thomas A D'Amico, David J Bentrem, David Cooke, Carlos Corvera
Journal of the National Comprehensive Cancer Network. 2023-04-01
Lectures
- Tislelizumab plus chemotherapy as first-line treatment for unresectable, locally advanced recurrent/metastatic esophageal squamous cell carcinoma.ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/23/2020
- From Standardization to Personalized Care: How to Use Molecular Diagnostics to Guide TreatmentASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/23/2020
- CD3+ and CD8+ tumor-infiltrating lymphocyte (TIL) densities to prognostically stratify DNA mismatch repair-deficient (dMMR) colon cancer patients (pts): NCCTG N0147 (A...2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
Other
- How Immunotherapy Is Transforming GI Cancer TreatmentHarry Yoon, MD, Op-Med
https://www.doximity.com/articles/01f7f77e-e73f-4d56-9d87-d82c9d8e9faf
UpToDate, Wolters Kluwer Health - 2013-03-12
Authored Content
- How Immunotherapy Is Transforming GI Cancer TreatmentJanuary 2019
Press Mentions
Addition of Tislelizumab to Chemotherapy in First-Line Treatment of Advanced or Metastatic Esophageal Squamous Cell CarcinomaMay 4th, 2023- BeiGene Announces Late-Breaking Data at ESMO GI Showing Overall Survival Benefit for Tislelizumab plus Chemotherapy in First-Line Advanced or Metastatic Esophageal Squamous Cell CarcinomaJune 30th, 2022
- Immunotherapy May Play Role in Treating Nonmetastatic Gastroesophageal CancerMay 16th, 2022
- Join now to see all
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
